EMEA-000398-PIP01-08
Key facts
| Invented name |
Dafiro HCT
|
| Active substance |
|
| Therapeutic area |
Cardiovascular diseases
|
| Decision number |
P/15/2009
|
| PIP number |
EMEA-000398-PIP01-08
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Essential hypertension
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Ltd.
E-mail: paediatric.enquiries@novartis.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|